검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Nivolumab & Ipilimumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Prostate Cancer |
Overview Indication | Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | checkpoint blockade-mediated eradication of bone metastasis: case report |
MoA Biomarker | biomarkers of T-cell infiltration and tumor fibrosis predict response to nivolumab ± ipili |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Efficacy of immune-based combinations across treatment lines in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.. With the rapid introduction of immune checkpoint inhibitors (ICIs) for advanced hepatocellular carcinoma (HCC), optimal treatment sequencing remains unclear. Lacking direct comparisons, we aimed to evaluate the efficacy and safety of systemic therapies … |
Clinical Primary efficacy | ORR 61.3% |
Clinical ORR | 61.3% |
Clinical Result source | ClinicalTrials.gov NCT04026412 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Nivolumab & Ipilimumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Prostate Cancer |
Overview Indication | Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | checkpoint blockade-mediated eradication of bone metastasis: case report |
MoA Biomarker | biomarkers of T-cell infiltration and tumor fibrosis predict response to nivolumab ± ipili |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Efficacy of immune-based combinations across treatment lines in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.. With the rapid introduction of immune checkpoint inhibitors (ICIs) for advanced hepatocellular carcinoma (HCC), optimal treatment sequencing remains unclear. Lacking direct comparisons, we aimed to evaluate the efficacy and safety of systemic therapies … |
Clinical Primary efficacy | ORR 61.3% |
Clinical ORR | 61.3% |
Clinical Result source | ClinicalTrials.gov NCT04026412 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교